Simultaneous detection of the status of the EGFR, HER2, and TOP2A genes may facilitate the development of effective therapeutic strategies to target gastric cancer, especially for determining those patients who may benefit most from a combination of therapies to target EGFR and HER2 together with a TOP2A inhibitor. Here, ERBB2 is linked to gastric cancer.